menu
    • menu
    [{"orgOrder":0,"company":"Versameb","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"RNA based therapies","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Versameb","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"","sponsorNew":"Versameb \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/ Undisclosed"},{"orgOrder":0,"company":"Versameb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"VMB-100","moa":"","graph1":"Urology","graph2":"Preclinical","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Versameb \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/ Not Applicable"},{"orgOrder":0,"company":"Versameb","sponsor":"Touchlight","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"VMB-100","moa":"","graph1":"Urology","graph2":"Preclinical","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Versameb \/ Versameb","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/ Versameb"},{"orgOrder":0,"company":"Versameb","sponsor":"Touchlight","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"VMB-100","moa":"","graph1":"Urology","graph2":"Preclinical","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Versameb \/ Touchlight","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/ Touchlight"}]

    Find Clinical Drug Pipeline Developments & Deals by Versameb

    Menu

    Versameb

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Versameb

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Versameb

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VMB-100

                            Therapeutic Area : Urology

                            Study Phase : Preclinical

                            Sponsor : Touchlight

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Touchlight’s Enzymatic Doggybone DNA used in the Manufacture of Versameb’s VMB-100 for First-in-human Clin...

                            Details : VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), is being developed to treat chronic stress urinary incontinence (SUI).

                            Brand Name : VMB-100

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 21, 2023

                            Lead Product(s) : VMB-100

                            Therapeutic Area : Urology

                            Highest Development Status : Preclinical

                            Sponsor : Touchlight

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Versameb

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Versameb

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VMB-100

                            Therapeutic Area : Urology

                            Study Phase : Preclinical

                            Recipient : Touchlight

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Touchlight and Versameb Announce GMP Manufacturing Supply Agreement

                            Details : The agreement enables Versameb to use Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology to support the development of novel mRNA-based therapeutics, including VMB-100, addressing unmet needs in urology and oncology.

                            Brand Name : VMB-100

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 01, 2022

                            Lead Product(s) : VMB-100

                            Therapeutic Area : Urology

                            Highest Development Status : Preclinical

                            Recipient : Touchlight

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Versameb

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Versameb

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VMB-100

                            Therapeutic Area : Urology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Versameb to Present Novel Data on Its Lead Asset, VMB-100 at 9th International mRNA Health Conference

                            Details : VMB-100 has demonstrated first-in-class potential for treatment for Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter. VMB-100 shows therapeutic potential in Stress U...

                            Brand Name : VMB-100

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 04, 2021

                            Lead Product(s) : VMB-100

                            Therapeutic Area : Urology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Versameb

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Versameb

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA based therapies

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $6.3 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Versameb Raises CHF 6 Million and Strengthens Team to Advance its VERSagile Technology Platform Towards Clinic...

                            Details : Molecular engineering mRNA sequences with the VERSagile technology platform generates molecules optimized for improved protein secretion and allows for modulation of different therapeutic targets.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 15, 2020

                            Lead Product(s) : RNA based therapies

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $6.3 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth